Companies › Diagonal Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Cardiovascular; next expected readout Nov 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| DIAG723 Bispecific agonist monoclonal antibody targeting ALK-1 and BMPRII | ALK1, BMPR2 | Phase 1 | Hereditary Hemorrhagic Telangiectasia | Nov 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07623525 | DIAG723 | Phase 1 | Hereditary Hemorrhagic Telangiectasia | Cardiovascular | Nov 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.